Literature DB >> 21389854

Treatments for corneal neovascularization: a review.

Deepak Gupta1, Chris Illingworth.   

Abstract

Corneal neovascularization (CNV) may be a physiological response to various stimuli, but a chronic and persistent upregulation of neoangiogenesis can result in pathological CNV. Pathological blood vessels are immature and lack structural integrity, predisposing the cornea to lipid exudation, inflammation, and scarring. CNV can therefore become a potentially blinding condition. In this review, we frame CNV in an epidemiological perspective, consider risk factors for CNV, provide an overview of CNV pathogenesis, and consider the impact of CNV on corneal transplantation. We consider treatments that are of largely historical interest, before reviewing contemporary medical and surgical treatments. Within medical treatments, we report on steroids, nonsteroidal anti-inflammatory agents, antivascular endothelial growth factor agents, and cyclosporine. Within surgical treatments, we report on the use of lasers, photodynamic therapy, superficial keratectomy, and diathermy/cautery-based treatments.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21389854     DOI: 10.1097/ICO.0b013e318201405a

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  38 in total

Review 1.  Small-interfering RNAs (siRNAs) as a promising tool for ocular therapy.

Authors:  A Guzman-Aranguez; P Loma; J Pintor
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

Review 2.  Management of high-risk corneal transplantation.

Authors:  Antonio Di Zazzo; Ahmad Kheirkhah; Tulio B Abud; Sunali Goyal; Reza Dana
Journal:  Surv Ophthalmol       Date:  2016-12-22       Impact factor: 6.048

Review 3.  Nanotechnology in corneal neovascularization therapy--a review.

Authors:  Lilian Gonzalez; Raymond J Loza; Kyu-Yeon Han; Suhair Sunoqrot; Christy Cunningham; Patryk Purta; James Drake; Sandeep Jain; Seungpyo Hong; Jin-Hong Chang
Journal:  J Ocul Pharmacol Ther       Date:  2013-02-20       Impact factor: 2.671

4.  Controlled release of dexamethasone sodium phosphate with biodegradable nanoparticles for preventing experimental corneal neovascularization.

Authors:  Bing Wang; Yating Tang; Yumin Oh; Nicholas W Lamb; Shiyu Xia; Zheng Ding; Baiwei Chen; María J Suarez; Tuo Meng; Vineet Kulkarni; Charles G Eberhart; Laura M Ensign; Walter J Stark; Justin Hanes; Qingguo Xu
Journal:  Nanomedicine       Date:  2019-01-21       Impact factor: 5.307

5.  Intrastromal delivery of bevacizumab using microneedles to treat corneal neovascularization.

Authors:  Yoo C Kim; Hans E Grossniklaus; Henry F Edelhauser; Mark R Prausnitz
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-09-11       Impact factor: 4.799

6.  Inhibitory effects of regorafenib, a multiple tyrosine kinase inhibitor, on corneal neovascularization.

Authors:  Halil Ibrahim Onder; Mesut Erdurmus; Yasin Yücel Bucak; Hüseyin Simavli; Murat Oktay; Ahmet Sahap Kukner
Journal:  Int J Ophthalmol       Date:  2014-04-18       Impact factor: 1.779

7.  Inhibitory effects of topical cyclosporine A 0.05% on immune-mediated corneal neovascularization in rabbits.

Authors:  Yasin Yücel Bucak; Mesut Erdurmus; Elçin Hakan Terzi; Aysel Kükner; Serdal Çelebi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-09-19       Impact factor: 3.117

Review 8.  Ocular delivery of macromolecules.

Authors:  Yoo Chun Kim; Bryce Chiang; Xianggen Wu; Mark R Prausnitz
Journal:  J Control Release       Date:  2014-07-03       Impact factor: 9.776

9.  An alkali-burn injury model of corneal neovascularization in the mouse.

Authors:  Chastain Anderson; Qinbo Zhou; Shusheng Wang
Journal:  J Vis Exp       Date:  2014-04-07       Impact factor: 1.355

10.  In vivo photoacoustic imaging for monitoring treatment outcome of corneal neovascularization with metformin eye drops.

Authors:  Kwok-Ho Lui; Shiying Li; Wai-Sum Lo; Yanjuan Gu; Wing-Tak Wong
Journal:  Biomed Opt Express       Date:  2021-05-21       Impact factor: 3.732

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.